Dobutamin

Phase 3Small molecule

CCompetence Network for Congenital Heart Defects

Dobutamin is one of 4 small molecule programs targeting Tetralogy of Fallot. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Tetralogy of FallotActive, not recruiting

Tetralogy of FallotPhase 3

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Tetralogy of Fallot

#DrugCompanyPhaseTrials

SGLT2 Inhibitor

Eli Lilly

Approved

1 2

Inderal

Mylan Pharmaceuticals Inc

Phase 1

—3

Dobutamin

CCompetence Network for Congenital Heart Defects

Phase 3

1 4

Alpha Tocopherol

TThammasat University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tetralogy of Fallot1 trial

Cardiac Function Under Stress for Early Detection of the Right Ventricular Insufficiency After Repair of Tetralogy of Fallot

Terminated·CCompetence Network for Congenital Heart Defects·Phase 3·NCT00564993·53 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dobutamin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dobutamin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dobutamin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Competence Network for Congenital Heart Defects company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCompetence Network for Congenital Heart Defects

Dobutamin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tetralogy of Fallot1 trial

References

Drug Info

Quick Facts

Related News